



1624
\$

Patent
Attorney's Docket No. 001560-390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Harukazu FUKAMI et al) Group Art Unit: 1624
Application No.: 09/763,213) Prior Examiner: Kahsay Habte
Filed: February 20, 2001) Confirmation No.: 3646
For: DESCRIPTION QUINAZOLINE)
DERIVATIVES AND)
PHARMACEUTICAL APPLICATIONS)
THEREOF)

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

AMENDMENT/REPLY TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a reply for the above-identified patent application.

- A Petition for Extension of Time is also enclosed.
- A Terminal Disclaimer and a check for [] \$55.00 (2814) [] \$110.00 (1814) to cover the requisite Government fee are also enclosed.
- Also enclosed is _____
- Small entity status is hereby claimed.
- Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [] \$370.00 (2801) [] \$740.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- Applicant(s) previously submitted ___, on ___, for which continued examination is requested.
- Applicant(s) request suspension of action by the Office until at least ___, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.
- No additional claim fee is required.

[] An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims		MINUS =		× \$18.00 (1202) =	
Independent Claims		MINUS =		× \$84.00 (1201) =	
If Amendment adds multiple dependent claims, add \$280.00 (1203)					
Total Amendment Fee					
If small entity status is claimed, subtract 50% of Total Amendment Fee					
TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT					

[] A claim fee in the amount of \$_____ is enclosed.

[] Charge \$_____ to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: *Malcolm M. Jans #39,300*
f/s Donna M. Meuth
Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: October 25, 2002



410C

PS

Patent
Attorney's Docket No. 001560-390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

In re Patent Application of)
Harukazu FUKAMI et al) Group Art Unit: 1624
Application No.: 09/763,213) Prior Examiner: Kahsay Habte
Filed: February 20, 2001) Confirmation No.: 3646
For: DESCRIPTION QUINAZOLINE)
DERIVATIVES AND)
PHARMACEUTICAL)
APPLICATIONS THEREOF)

OCT 30 2002
TECH CENTER 1600/2900

REPLY AND AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Office Action mailed April 25, 2002, please amend the above-identified application as follows.

IN THE ABSTRACT:

Please replace the Abstract with the new Abstract attached hereto.

IN THE SPECIFICATION:

Kindly replace the paragraph beginning at page 4, line 10, with the following:

--R¹ represents a hydroxyl group, an amino group, a C₁ to C₄ lower alkylamino

C | group which may be substituted with a carboxylic acid group, a C₇ and C₁₀ lower aralkylamino group which may be substituted with a carboxylic acid group, an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a carboxylic